Journal: Current Issues in Molecular Biology

Article Title: Associating Patient Responses with Drug Sensitivity in Non-Small Cell Lung Carcinoma Using an Immunoassay on Patient-Derived Cell Cultures

doi: 10.3390/cimb47040281

Figure Lengend Snippet: Clinical parameters of NSCLC patients included in our study.

Article Snippet: Vinorelbine, pemetrexed, and osimertinib were purchased from Selleckchem (Houston, TX, USA).

Techniques: Mutagenesis

Journal: Journal of Cellular and Molecular Medicine

Article Title: In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non–small‐cell lung cancer

doi: 10.1111/jcmm.14689

Figure Lengend Snippet: Thiostrepton combined with anti‐cancer drugs exhibits a synergistic effect on NSCLC growth. A, Fa‐CI plot represents the CI values and the Fa (fraction affected, cytotoxic effect) at different concentrations of thiostrepton (1.25, 2.5, and 5 μmol/L) in combination with different chemotherapeutic drugs (pemetrexed, cisplatin, gemcitabine) or gefitinib (5, 10, and 20 μmol/L) for 48 h in CL152 cells. A combination of thiostrepton and gemcitabine showed the highest synergistic effect among the combinations. The data were analysed by CompuSyn software. B, Thiostrepton was combined with gemcitabine at different dosing ratios (1:1, 1:2, 1:4 or 1:8) in CL141, CL152 and H1299 cells. All combinations demonstrated synergistic anti‐NSCLC effects. C, Western blotting assays for CL141 cells treated with thiostrepton and/or gemcitabine. The combination of thiostrepton and gemcitabine effectively reversed EMT and induced apoptosis. D, Comparative Western blotting assays of CL141 and CL152 cells with treatments of thiostrepton, gemcitabine, or thiostrepton plus gemcitabine. Thiostrepton treatment significantly suppressed the expression of β‐catenin (stemness marker) and Slug (EMT marker). When combined with gemcitabine, the suppressive effect was more pronounced in CL152 cells. E, Western blotting assays of CL141 (P) and CL141 spheres (S) treated with thiostrepton and/or gemcitabine. The combination of thiostrepton and gemcitabine effectively suppressed the elevated CD133 expression in the CL141 spheres and induced the apoptotic marker‐cleaved PARP

Article Snippet: Pemetrexed, gefitinib and gemcitabine were purchased from LC Laboratories, while thiostrepton and cisplatin were acquired from Sigma and Selleckchem, respectively.

Techniques: Software, Western Blot, Expressing, Marker